MX2020003806A - Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. - Google Patents

Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.

Info

Publication number
MX2020003806A
MX2020003806A MX2020003806A MX2020003806A MX2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A MX 2020003806 A MX2020003806 A MX 2020003806A
Authority
MX
Mexico
Prior art keywords
cancer
prevention
treatment
monoclonal antibodies
antibodies targeting
Prior art date
Application number
MX2020003806A
Other languages
English (en)
Inventor
David Weiner
Elizabeth Duperret
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Publication of MX2020003806A publication Critical patent/MX2020003806A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describe una composición que incluye una secuencia de ácidos nucleicos recombinantes que codifica un anticuerpo o fragmento de este que se dirige a CTLA-4; la descripción también proporciona un método para prevenir y/o tratar una enfermedad, tal como el cáncer, en un sujeto usando la composición de la invención.
MX2020003806A 2017-10-06 2018-10-03 Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer. MX2020003806A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762569470P 2017-10-06 2017-10-06
PCT/US2018/054137 WO2019070834A1 (en) 2017-10-06 2018-10-03 MONOCLONAL DNA ANTIBODIES TARGETING CTLA-4 FOR THE TREATMENT AND PREVENTION OF CANCER

Publications (1)

Publication Number Publication Date
MX2020003806A true MX2020003806A (es) 2020-11-09

Family

ID=65995298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003806A MX2020003806A (es) 2017-10-06 2018-10-03 Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.

Country Status (11)

Country Link
US (1) US20200283525A1 (es)
EP (1) EP3691694A4 (es)
JP (1) JP2020536114A (es)
KR (1) KR20200060759A (es)
CN (1) CN111971071A (es)
AU (1) AU2018345715A1 (es)
BR (1) BR112020006879A2 (es)
CA (1) CA3078458A1 (es)
MX (1) MX2020003806A (es)
RU (1) RU2020115161A (es)
WO (1) WO2019070834A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963226T3 (es) 2016-12-07 2024-03-26 Agenus Inc Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos
WO2023064841A1 (en) * 2021-10-13 2023-04-20 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
BRPI0812913B8 (pt) * 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
KR102017898B1 (ko) * 2010-05-14 2019-09-04 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
BR112013006699A2 (pt) * 2010-09-24 2016-06-14 Oncos Therapeutics Oy vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
US20160355573A1 (en) * 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
CN105658799A (zh) * 2013-10-07 2016-06-08 普雷斯蒂奇生物制药私人有限公司 用于抗体表达的双顺反子表达载体以及用其生产抗体的方法
CN105829341A (zh) * 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 Dna抗体构建体及其使用方法
ES2727137T3 (es) * 2014-08-28 2019-10-14 Halozyme Inc Terapia combinada con una enzima de degradación de hialuronano y un inhibidor de puntos de control inmunitario
KR20170085131A (ko) * 2014-12-01 2017-07-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Dna 항체 작제물 및 그 이용 방법
EP3400023A1 (en) * 2016-01-10 2018-11-14 ModernaTX, Inc. Therapeutic mrnas encoding anti ctla-4 antibodies
US11896654B2 (en) * 2016-05-05 2024-02-13 The Trustees Of The University Of Pennsylvania DNA monoclonal antibodies targeting checkpoint molecules

Also Published As

Publication number Publication date
KR20200060759A (ko) 2020-06-01
EP3691694A4 (en) 2021-07-07
JP2020536114A (ja) 2020-12-10
CA3078458A1 (en) 2019-04-11
RU2020115161A (ru) 2021-11-08
AU2018345715A8 (en) 2020-05-28
US20200283525A1 (en) 2020-09-10
EP3691694A1 (en) 2020-08-12
RU2020115161A3 (es) 2022-01-28
AU2018345715A1 (en) 2020-05-21
BR112020006879A2 (pt) 2020-10-06
CN111971071A (zh) 2020-11-20
WO2019070834A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
MX2024000125A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MX2017014955A (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
EA201890175A1 (ru) Антитела к cd40
PE20190737A1 (es) Anticuerpos anti-cd27
MD20170031A2 (ro) Anticorpi anti-LAG3 şi fragmente de legare a antigenului
UA117364C2 (uk) Похідні аматоксину
PH12019502298A1 (en) Monoclonal antibody to pd-l1
CY1121734T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
BR112017025036A2 (pt) peptídeo; ácido nucleico; parcela de ligação; composição farmacêutica; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação; peptídeos e/ou ácidos nucleicos e/ou parcelas de ligação para uso; e ácido nucleico para uso
MX2024006292A (es) Anticuerpos monoclonales de adn dirigidos al virus de la influenza.
BR112017013420A2 (pt) anticorpo adam17 humanizado
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
EA202092121A1 (ru) Антитела против cd73 и их применения
EA202092981A1 (ru) Антитела к l1cam и их применение